These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 9757151)

  • 1. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Counihan M; Graf JA; Durol AL; Mertzanis P; Duan SX; Wright CE; Shader RI
    Clin Pharmacol Ther; 1998 Sep; 64(3):278-85. PubMed ID: 9757151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences.
    Greenblatt DJ; Wright CE; von Moltke LL; Harmatz JS; Ehrenberg BL; Harrel LM; Corbett K; Counihan M; Tobias S; Shader RI
    Clin Pharmacol Ther; 1998 Sep; 64(3):237-47. PubMed ID: 9757147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.
    Ito K; Ogihara K; Kanamitsu S; Itoh T
    Drug Metab Dispos; 2003 Jul; 31(7):945-54. PubMed ID: 12814973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alprazolam-ritonavir interaction: implications for product labeling.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
    Clin Pharmacol Ther; 2000 Apr; 67(4):335-41. PubMed ID: 10801241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.
    von Moltke LL; Greenblatt DJ; Harmatz JS; Duan SX; Harrel LM; Cotreau-Bibbo MM; Pritchard GA; Wright CE; Shader RI
    J Pharmacol Exp Ther; 1996 Feb; 276(2):370-9. PubMed ID: 8632299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
    Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
    Masica AL; Mayo G; Wilkinson GR
    Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
    Wandel C; Lang CC; Cowart DC; Girard AF; Bramer S; Flockhart DA; Wood AJ
    Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro complex formation and inhibition of hepatic cytochrome P450 activity by different macrolides and tiamulin in goats and cattle.
    Zweers-Zeilmaker WM; Van Miert AS; Horbach GJ; Witkamp RF
    Res Vet Sci; 1999 Feb; 66(1):51-5. PubMed ID: 10088712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Mertzanis P; Graf JA; Durol AL; Counihan M; Roth-Schechter B; Shader RI
    Clin Pharmacol Ther; 1998 Dec; 64(6):661-71. PubMed ID: 9871431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
    Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo.
    Mitra AK; Thummel KE; Kalhorn TF; Kharasch ED; Unadkat JD; Slattery JT
    Clin Pharmacol Ther; 1995 Nov; 58(5):556-66. PubMed ID: 7586950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
    Polasek TM; Miners JO
    Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential impairment of triazolam and zolpidem clearance by ritonavir.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
    J Acquir Immune Defic Syndr; 2000 Jun; 24(2):129-36. PubMed ID: 10935688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
    Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
    Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin.
    Yeates RA; Laufen H; Zimmermann T; Schumacher T
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):577-9. PubMed ID: 9455717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
    Ushiama H; Echizen H; Nachi S; Ohnishi A
    Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethanol inhibits in-vitro metabolism of nifedipine, triazolam and testosterone in human liver microsomes.
    Patki KC; Greenblatt DJ; von Moltke LL
    J Pharm Pharmacol; 2004 Aug; 56(8):963-6. PubMed ID: 15285839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.